StockData
GH Research PLC logo

GH Research PLC (GHRS) stock

GHRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 1/30
$18.27−0.48 (-2.56%)

Close on Nov 17, 2026Market cap $1.13BP/E –Yield –

GH Research r&d expenses

Research and development expenses are spending on new products and technology.

GH Research's R&D Expenses for the twelve months ending Jun 30, 2026 was $46.73M, up 39.9% year over year. For fiscal 2025 it was $38.77M, up 10.7% from the year before. The highest annual figure on record is $38.77M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$38.77M+10.7%
FY2024Dec 31, 2024$35.02M+17.4%
FY2023Dec 31, 2023$29.82M+45.6%
FY2022Dec 31, 2022$20.48M+139.5%
FY2021Dec 31, 2021$8.55M+2430.5%
FY2020Dec 31, 2020$338.00K+14.2%
FY2019Dec 31, 2019$296.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$12.40M+38.4%
Q1 FY2026Mar 31, 2026$12.38M+57.7%
Q4 FY2025Dec 31, 2025$11.39M+38.8%
Q3 FY2025Sep 30, 2025$10.57M+25.8%
Q2 FY2025Jun 30, 2025$8.96M-8.2%
Q1 FY2025Mar 31, 2025$7.85M-9.3%
Q4 FY2024Dec 31, 2024$8.21M-0.5%
Q3 FY2024Sep 30, 2024$8.40M+18.5%
Q2 FY2024Jun 30, 2024$9.76M+35.9%
Q1 FY2024Mar 31, 2024$8.66M+18.5%
Q4 FY2023Dec 31, 2023$8.25M+19.4%
Q3 FY2023Sep 30, 2023$7.09M+53.4%
Q2 FY2023Jun 30, 2023$7.18M+69.2%
Q1 FY2023Mar 31, 2023$7.31M–
Q4 FY2022Dec 31, 2022$6.91M–
Q3 FY2022Sep 30, 2022$4.62M–
Q2 FY2022Jun 30, 2022$4.24M–

More GH Research figures

See a number that looks wrong?